Clinical trials: Prostate Cancer, open to volunteers
Malignancy
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.
- Trial name
- NCT05761366
- Testing
- Al18F-PSMA-BCH PET/CT
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Cancer (Adenocarcinoma)
Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery
As part of a feasibility study, it's planned to use a 3D virtual mixed reality model with prostate cancer patients who show signs of lymph node metastasis and are scheduled for surgery.
- Trial name
- NICE-PSMA (NCT07129551)
- Testing
- preop virtual 3D model, postop 3D model
- Where
- 2 sites in Germany
- Volunteers
- 102 people
- Sponsor
- Martini-Klinik am UKE GmbH
Prostate Cancer
Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.
- Trial name
- IMAGINED (NCT05882253)
- Testing
- Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- University of California, San Diego
Metastatic Prostate Adenocarcinoma, PSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.
- Trial name
- KuPSMALu (NCT06850545)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Kuopio University Hospital
Prostate Cancer
Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis
The goal of this multicenter clinical trial is to compare the cancer detection rates of MRI artificial intelligence-guided cTB (AI-cTB) and routine cTB, and explore the added value of using AI for the guidance of cTB.
- Trial name
- NCT06392737
- Testing
- MRI-AI guided cognitive prostate targeted biopsy, Routine cognitive prostate targeted biopsy
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Peking University First Hospital
Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia)
Sonablate HIFU International Registry for PC & BPH Patients
The SONA FUSION Registry is an observational study designed to evaluate the long-term effectiveness and safety of the Sonablate High-Intensity Focused Ultrasound (HIFU) system.
- Conditions
- Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia), Prostate Cancer; Benign Prostatic Hyperplasia
- Trial name
- SONAFUSION (NCT07757490)
- Testing
- High Intensity Focused Ultrasound
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Sonablate
Prostate Cancer
Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability Testing
This protocol describes development and user testing of an educational shared decision making intervention to help men with prostate cancer who are on active surveillance make decisions with their health care providers about if…
- Trial name
- NCT05497024
- Testing
- Interviews, Surveys
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer (Adenocarcinoma)
Evaluation of the PROSTia Test in Patients Undergoing Prostate Biopsy
The investigators are interested here in the contribution of a new prostate cancer screening method and, more specifically, in the new and somewhat futuristic approach of artificial intelligence in the development of new, more…
- Trial name
- PROSTIA- BP (NCT06931496)
- Testing
- PROSTia test
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Central Hospital, Nancy, France
Prostate Cancer
Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer
Focal therapy (FT) is a new approach to treating localized prostate cancer. Instead of treating the entire prostate, it targets only the cancerous areas while preserving healthy tissue.
- Trial name
- FLAME-PC (NCT07282808)
- Testing
- Molecular Evaluation for Risk of Recurrence after FT
- Where
- Singapore
- Volunteers
- 130 people
- Sponsor
- Singapore General Hospital
Prostate Cancer, Cervical Cancer
Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)
The accuracy of radiotherapy can be increased by correcting for geometric uncertainties and changes between radiotherapy fractions.
- Conditions
- Prostate Cancer, Cervical Cancer, Bladder Cancer, Lung Cancer
- Trial name
- FASCINATE (NCT06691776)
- Testing
- online CBCT-guided adaptive radiation therapy using a new software
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Cognitive and Fusion Prostatic Biopsy
The goal of this study is to compare two different prostate biopsy techniques used to detect prostate cancer. These techniques are cognitive-targeted biopsy (CTB) and magnetic resonance imaging-ultrasound fusion-targeted…
- Trial name
- CTB-FTB (NCT07306741)
- Testing
- Cognitive-targeted prostate biopsy
- Where
- 2 sites in Egypt
- Volunteers
- 80 people
- Sponsor
- Menoufia University
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Prostate Cancer
Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)
This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia
- Trial name
- ProAMFocal (NCT06491056)
- Testing
- Focal Therapy for Prostate Cancer
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- Singapore General Hospital
Depression, Cancer
Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)
The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.
- Conditions
- Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT06811454
- Testing
- MINDSET, Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment.
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Trial name
- ARPEGGIO (NCT07393867)
- Testing
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Martin T. King, MD, PhD
Prostatic Neoplasms
Radical Prostatectomy Versus Radical Radiotherapy for Locally Advanced Prostate Cancer
This prospective, open randomized clinical trial seeks to investigate whether radical prostatectomy with androgen deprivation therapy improves prostate-cancer specific survival and quality of life in comparison with radical…
- Trial name
- NCT04093375
- Testing
- Radical Prostatectomy, Radical Radiotherapy
- Volunteers
- 600 people
- Sponsor
- Tongji Hospital
Elderly, Prostate Cancer
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer.
- Trial name
- NCT06824818
- Testing
- LHRH Agonist Therapy Discontinuation
- Where
- 2 sites in United States
- Volunteers
- 155 people
- Sponsor
- University of Chicago
Prostate Cancer
The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer
Lead4Care is an observational, open-label, multicenter study evaluating the effectiveness, tolerance, and cost-effectiveness of triple against double therapy in matched groups of mHSPC patients with high tumor burden.
- Trial name
- Lead4Care (NCT06446401)
- Testing
- ADT + NHT + Docetaxel, ADT + NHT
- Where
- 2 sites in Sweden
- Volunteers
- 1,400 people
- Sponsor
- Uppsala University
Prostate Cancer Metastatic Disease, Prostate Cancers
Using FAPI PET/MRI to Evaluate Prostate Cancer
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue.
- Trial name
- NCT06675357
- Testing
- FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Multiparametric MRI, Lesion PI-RADS 3
The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)
Prostate Specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT), an imaging modality focusing on a protein overexpressed by prostate cancer cells, has revolutionised the staging of both newly…
- Trial name
- PANDORA (NCT06867588)
- Testing
- PSMA PET
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- Jules Bordet Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.